LIMERICK, Ireland--(BUSINESS WIRE)--Firecrest Clinical, an e-technology solution provider that definitively enhances investigator site performance, announces the appointment of Alan Horgan as Chief Executive Officer.
Mr. Horgan, who graduated from Warwick University, England, with a Bachelor of Science in biochemistry, began working in the drug development sector in 1997 and moved to the United States in 2000. In 2009, he began working with Firecrest to establish their operations in the US and globalize their business.
Possessing many years of experience within the pharmaceutical industry, Mr. Horgan has held several high-level positions in the healthcare clinical research organization (CRO) sector, most notably at MDS Pharma Services as group vice president, late stage development, and at Covance as corporate senior vice president and president, clinical development. His broad experience of clinical development and the challenges of running complex global clinical trials make him well suited to build on the strong foundations that Firecrest has established in Europe and the US.
Gerard Ryan, Chairman of Firecrest, says, “The 10 years that Mr. Horgan has spent working with large CROs, coupled with his deep understanding of the challenges facing investigative sites, will undoubtedly lead Firecrest in its quest to drive site performance in complex clinical trials. We are happy to have him on board.”
Firecrest, established in 2001, is the innovator of e-technology solutions that solve the many challenges facing clinical trial management and poor site performance. Firecrest’s products and services help investigators run complex trials by specifically improving compliance, consistency, and quality of execution of all study-related procedures and activities conducted by investigator site staff and monitoring teams.
About Firecrest Clinical Firecrest Clinical definitively improves clinical site performance through e-technology solutions that provide investigator training and study management tools. Reducing trial costs and protocol deviation, Firecrest Clinical is proven to enhance compliance, consistency, and the quality of execution for all study-related procedures and activities. Firecrest Clinical works to increase patient recruitment by 10-12 percent and produces much cleaner data with a 40-50 percent reduction in data queries. For more information about Firecrest Clinical’s game-changing technology, visit www.firecrestclinical.com.
Contact:
SCORR Marketing Kelly Sladek, 308-237-5567 Kelly@scorrmarketing.com
